Novo Nordisk snaps up RNAi partner Dicerna in $3.3bn takeove...

Danish drugmaker Novo Nordisk must like what it has seen in its two-year-old alliance with gene-silencing specialist Dicerna Pharma – it has just agreed to acquire the biotech for $3.3 bill

Race for hepatitis B drug intensifies as Antios raises $96m ...

Antios has raised $96 million in Series B financing to support the ongoing phase 2 development of its hepatitis B drug candidate, ATI-2173.

Novo Nordisk’s gene silencing alliance with Dicerna bears fi...

Two years after starting to work together, Novo Nordisk and Dicerna have selected the first candidate from a joint project to find new, gene-silencing drugs for liver-related cardiometaboli

FDA approves Alnylam's ultra-rare disease drug Oxlumo

The FDA has approved Alnylam’s gene silencing drug Oxlumo, the first treatment for primary hyperoxaluria type 1 (PH1), an ultra-rare and life-threatening genetic disorder.

Alnylam files its third RNAi drug lumasiran in rare kidney d...

Novo bolsters R&D pipeline with RNAi therapies from Dicerna

Novo Nordisk has further bolstered its liver disease R&D pipeline, signing a deal with US biotech Dicerna to discover and develop RNA-blocking therapies for diseases such as NASH and ty